Monday, February 16, 2026
28
C
Bengaluru
Hot topics
If Strategy is Commodity, How Can Organisations Ensure Differentiation?
Strategy and strategic planning are perhaps the most hyped-up...
Breaking Performance Barriers
Articles by K. Hariram, Pankaj Mehrotra, Rinkesh Shah, Gopal Kishore, Amaninder S. Dhillon, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal, and Mahendra Kumar Rai
Pharm-Uneasy As Leadership Changes Take Effect
India’s digital health landscape saw a significant leadership change...
“Sales at Any Cost” is Not Sustainable in the Long Run
For commercial organisations, profits are important. But it cannot be 'at any cost' and certainly not at the cost of human life. As healthcare providers helping to mitigate the pain and misery of millions of human beings, we need to remember that charity begins at home.
Interview with Ajit Singh, Chairman, ACG
Special interview with the Chairman of ACG and an invitation to "Pharmaceutical Marketing in the New Age" - a conference presented by ACG in partnership with MedicinMan
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Hot topics
Why Most AI Healthcare Tools Stall at the Pilot Stage
Artificial intelligence (AI) in healthcare consistently demonstrates remarkable technical...
How Did Telma Become a 1000+ Cr Brand?
The untold story of Glenmark's phenomenal success in building...
Healthcare Disruption – Will Ola, Swiggy, Pharmaeasy, and Hospitals Converge to Deliver Health Care on Call at Your Doorstep?
How long before digital Unicorns like Ola, Swiggy, Pharmeasy, and many others realize the humongous opportunity of delivering health care at the doorstep?
Imagine an app like Ola, where instead of entering where you want to go, you enter the nature of your medical need/emergency and search and find a range of hospitals/doctors/paramedics who can act as the first responders and reach your home in an ambulance or a motorbike with an HCP as a pillion rider with all necessary equipment from the thermometer to defibrillator depending on the nature of the medical care needed and triage and route you/your loved ones to the nearest hospital with an indicative cost of treatment in partnership with health insurance companies?
Top 25 Indian Pharma Companies by Revenues in 2024
India pharma is crucial for global healthcare, providing affordable...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Newsletter
Get important news delivered directly to your inbox and stay connected!